Changes of HbA1c variability after the switch to a longer-acting insulin analog in people with type 1 diabetes

被引：0

作者：

Watanabe, Hirotaka ^{[1
]}

Takahara, Mitsuyoshi ^{[2
]}

Katakami, Naoto ^{[1
]}

Shimomura, Iichiro ^{[1
]}

机构：

[1] Osaka Univ, Dept Metab Med, Grad Sch Med, Osaka, Japan

[2] Osaka Univ, Dept Diabet Care Med, Grad Sch Med, Osaka, Japan

来源：

JOURNAL OF DIABETES INVESTIGATION | 2023年 / 14卷 / 02期

关键词：

HbA1c variability; Insulin; Type; 1; diabetes; GLYCEMIC VARIABILITY; GLARGINE; DEGLUDEC;

D O I：

10.1111/jdi.13941

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study investigated whether longer-acting basal analogs (insulin degludec and insulin glargine U300) could reduce visit-to-visit hemoglobin A1c (HbA1c) variability in patients with type 1 diabetes. Ninety adults with type 1 diabetes for whom the basal insulin was switched to a longer-acting insulin analog were analyzed retrospectively. The coefficient of variation of HbA1c levels (CV-HbA1c) during the year before and after the switch was compared. The CV-HbA1c after the switch was not significantly different from that before the switch (4.39 +/- 2.24% vs 4.25 +/- 2.07%; P = 0.506). The linear regression model revealed that CV-HbA1c before the switch was independently associated with the change of CV-HbA1c (regression coefficient per standard deviation = -0.568, P < 0.001), whereas the other variables were not (all P > 0.05). In conclusion, CV-HbA1c remained unchanged after the switch on average, but CV-HbA1c before the switch was associated with the decrease of CV-HbA1c in individuals with type 1 diabetes.

引用

页码：259 / 262

页数：4

共 12 条

[1] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 [J].

American Diabetes Association Professional Practice Committee .

DIABETES CARE, 2022, 45 :S125-S143

[2] EFFECT OF INTENSIVE DIABETES TREATMENT ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN ADOLESCENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS - DIABETES CONTROL AND COMPLICATIONS TRIAL [J].

不详 .

JOURNAL OF PEDIATRICS, 1994, 125 (02) :177-188

[3] Type 1 diabetes [J].

DiMeglio, Linda A. ;

Evans-Molina, Carmella ;

Oram, Richard A. .

LANCET, 2018, 391 (10138) :2449-2462

[4] HbA1c variability and long-term glycemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background [J].

Garcia Franco da Rosa, Larissa Carolina ;

Zajdenverg, Lenita ;

Souto, Debora Lopes ;

Dantas, Joana Rodrigues ;

Rocha Pinto, Marcus Vinicius ;

da Costa Mendes de Salles, Gil Fernando ;

Rodacki, Melanie .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (09) :610-615

[5] Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis [J].

Gorst, Catherine ;

Kwok, Chun Shing ;

Aslam, Saadia ;

Buchan, Iain ;

Kontopantelis, Evangelos ;

Myint, Phyo K. ;

Heatlie, Grant ;

Loke, Yoon ;

Rutter, Martin K. ;

Mamas, Mamas A. .

DIABETES CARE, 2015, 38 (12) :2354-2369

[6] Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial [J].

Heller, Simon ;

Buse, John ;

Fisher, Miles ;

Garg, Satish ;

Marre, Michel ;

Merker, Ludwig ;

Renard, Eric ;

Russell-Jones, David ;

Philotheou, Areti ;

Francisco, Ann Marie Ocampo ;

Pei, Huiling ;

Bode, Bruce .

LANCET, 2012, 379 (9825) :1489-1497

[7] New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4) [J].

Home, Philip D. ;

Bergenstal, Richard M. ;

Bolli, Geremia B. ;

Ziemen, Monika ;

Rojeski, Maria ;

Espinasse, Melanie ;

Riddle, Matthew C. .

DIABETES CARE, 2015, 38 (12) :2217-2225

[8] Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes The SWITCH 1 Randomized Clinical Trial [J].

Lane, Wendy ;

Bailey, Timothy S. ;

Gerety, Gregg ;

Gumprecht, Janusz ;

Philis-Tsimikas, Athena ;

Hansen, Charlotte Thim ;

Nielsen, Thor S. S. ;

Warren, Mark .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (01) :33-44

[9] HbA1c variability and long-term glycemic control are linked to peripheral neuropathy in patients with type 1 diabetes [J].

Pinto, M. V. ;

Rosa, L. C. G. F. ;

Pinto, L. F. ;

Dantas, J. R. ;

Salles, G. F. ;

Zajdenverg, L. ;

Rodacki, M. ;

Lima, M. A. .

DIABETOLOGY & METABOLIC SYNDROME, 2020, 12 (01)

[10]

Scott Emma S, 2019, BMJ Open, V9, pe033059, DOI 10.1136/bmjopen-2019-033059

← 1 2 →